In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Massari, F. et al. Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. Clin. Genitourin. Cancer 11, 471–476 (2013).
Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016).
Choueiri, T. K. et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N. Engl. J. Med. 390, 1359–1371 (2024).
Mollica, V. & Massari, F. Adjuvant treatment in renal cell carcinoma: a never-ending story? Lancet 403, 433–434 (2024).
Rosellini, M. et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat. Rev. Urol. 20, 133–157 (2023).
Barragan-Carrillo, R., Govindarajan, A., Rock, A., Sperandio, R. C. & Pal, S. K. Managing metastatic renal cell carcinoma after progression on immunotherapy. Hematol. Oncol. Clin. North Am. 37, 965–976 (2023).
Bourlon, M. T., Valdez, P., Choueiri, T. K. & Lam, E. Using clinical characteristics to guide treatment of recurrent RCC after adjuvant pembrolizumab. ASCO Daily News https://dailynews.ascopubs.org/do/using-clinical-characteristics-guide-treatment-recurrent-rcc-after-adjuvant (2024).
Kluger, H. M. et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J. Immunother. Cancer 8, e000398 (2020).
Rosellini, M., Tassinari, E., Marchetti, A., Mollica, V. & Massari, F. Re: atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Eur. Urol. 85, 97–98 (2024).
Choueiri, T. K. et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 24, 553–562 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.M. has received research support and/or honoraria from Astellas, BMS, Janssen, Ipsen, MSD and Pfizer outside the submitted work. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Massari, F., Rosellini, M. & Mollica, V. Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning. Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00896-6
Published:
DOI: https://doi.org/10.1038/s41585-024-00896-6
